Heron Therapeutics 将来の成長

Future 基準チェック /46

Heron Therapeuticsは、69.2%と17.9%でそれぞれ年率69.2%で利益と収益が成長すると予測される一方、EPSはgrowで69.4%年率。

主要情報

69.2%

収益成長率

69.4%

EPS成長率

Biotechs 収益成長	28.0%
収益成長率	17.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	01 Nov 2024

今後の成長に関する最新情報

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Mar 15

Recent updates

Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%

Aug 08

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

May 30

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Apr 16

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Mar 15

Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 15

Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%

Dec 22

Need To Know: Analysts Just Made A Substantial Cut To Their Heron Therapeutics, Inc. (NASDAQ:HRTX) Estimates

Aug 11

Shareholders May Be A Bit More Conservative With Heron Therapeutics, Inc.'s (NASDAQ:HRTX) CEO Compensation For Now

Jun 11

業績と収益の成長予測

NasdaqCM:HRTX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	221	38	N/A	N/A	2
12/31/2025	180	1	N/A	N/A	3
12/31/2024	148	-17	N/A	N/A	3
6/30/2024	136	-48	-23	-21	N/A
3/31/2024	132	-81	-45	-43	N/A
12/31/2023	127	-111	-60	-59	N/A
9/30/2023	123	-120	-100	-99	N/A
6/30/2023	118	-137	-128	-127	N/A
3/31/2023	114	-151	-129	-128	N/A
12/31/2022	108	-182	-149	-147	N/A
9/30/2022	98	-217	-156	-155	N/A
6/30/2022	95	-227	-174	-171	N/A
3/31/2022	90	-232	-209	-205	N/A
12/31/2021	86	-221	-206	-203	N/A
9/30/2021	86	-228	-216	-211	N/A
6/30/2021	83	-234	-204	-200	N/A
3/31/2021	83	-228	-198	-194	N/A
12/31/2020	89	-227	-192	-185	N/A
9/30/2020	103	-223	-167	-159	N/A
6/30/2020	126	-198	-149	-143	N/A
3/31/2020	140	-193	-116	-108	N/A
12/31/2019	146	-205	-132	-125	N/A
9/30/2019	140	-196	-138	-131	N/A
6/30/2019	117	-201	-153	-141	N/A
3/31/2019	98	-190	-190	-179	N/A
12/31/2018	77	-179	-201	-192	N/A
9/30/2018	59	-192	-212	-205	N/A
6/30/2018	47	-195	-213	-210	N/A
3/31/2018	39	-199	N/A	-181	N/A
12/31/2017	31	-197	N/A	-170	N/A
9/30/2017	22	-183	N/A	-162	N/A
6/30/2017	13	-190	N/A	-157	N/A
3/31/2017	5	-190	N/A	-152	N/A
12/31/2016	1	-173	N/A	-134	N/A
9/30/2016	N/A	-156	N/A	-119	N/A
6/30/2016	N/A	-131	N/A	-102	N/A
3/31/2016	N/A	-110	N/A	-91	N/A
12/31/2015	N/A	-98	N/A	-79	N/A
9/30/2015	N/A	-87	N/A	-68	N/A
6/30/2015	N/A	-83	N/A	-68	N/A
3/31/2015	N/A	-79	N/A	-64	N/A
12/31/2014	N/A	-76	N/A	-60	N/A
9/30/2014	N/A	-70	N/A	-57	N/A
6/30/2014	N/A	-63	N/A	-50	N/A
3/31/2014	N/A	-60	N/A	-49	N/A

アナリストによる今後の成長予測

収入対貯蓄率: HRTXは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: HRTX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: HRTX今後 3 年以内に収益を上げることが予想されます。

収益対市場: HRTXの収益 ( 17.9% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: HRTXの収益 ( 17.9% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: HRTXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Heron Therapeutics 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 22%

Forecast breakeven date pushed back to 2026

Consensus estimates of losses per share improve by 58%

Forecast breakeven date moved forward to 2025

Consensus estimates of losses per share improve by 51%

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Recent updates

Heron Therapeutics, Inc. Announces Appointment of Michael Kaseta to Board of Directors

Heron Therapeutics, Inc. Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

Heron Therapeutics, Inc. Appoints Brett Fleshman as Chief Business Officer

Consensus EPS estimates fall by 22%

Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%

Forecast breakeven date pushed back to 2026

Second quarter 2024 earnings: EPS misses analyst expectations

Heron Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Heron Therapeutics, Inc. Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Heron Therapeutics, Inc. Announces Acceptance of the Prior Approval Supplement Application for Zynrelef® Vial Access Needle

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Heron Therapeutics, Inc. Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

Consensus estimates of losses per share improve by 58%

Forecast breakeven date moved forward to 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Heron Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Heron Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Consensus estimates of losses per share improve by 51%

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Heron Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Price target decreased by 8.7% to US$6.67

Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Forecast to breakeven in 2026

Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023

Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%

Consensus EPS estimates upgraded to US$0.90 loss

CEO & Director recently bought US$138k worth of stock

Price target decreased by 13% to US$6.50

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024

Heron Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Market cap size

Consensus EPS estimates fall by 30%

Second quarter 2023 earnings: EPS misses analyst expectations

Heron Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Executive Vice President and Chief Development Officer

Heron Therapeutics, Inc. Announces Management Changes

Consensus EPS estimates fall by 17%

First quarter 2023 earnings: EPS misses analyst expectations

Heron Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Rubric Capital Management Engages with Heron Therapeutics

Forecast to breakeven in 2025

Heron Therapeutics, Inc. Provides Sales Guidance for the Full Year 2023

Forecast to breakeven in 2025

Heron Therapeutics, Inc. Announces the Submission of Supplemental New Drug Application for ZYNRELEF

Price target decreased to US$10.08

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Heron Therapeutics, Inc. Provides Sales Guidance for the Year 2022

Heron Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Heron Therapeutics, Inc. Announces U.S. FDA Approval of APONVIE™ (HTX-019) for Prevention of Postoperative Nausea and Vomiting

Heron wins FDA nod for post-operative agent to address nausea and vomiting

Heron Therapeutics, Inc. announced that it has received $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Heron Therapeutics, Inc. announced that it expects to receive $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC and other investors

Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?

Heron Therapeutics Q2 2022 Earnings Preview

Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan

Price target decreased to US$17.08

Heron Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022

Heron Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022